The natural history of hepatitis C-A quandary (Q77598664)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

0 references

1 reference

title

The natural history of hepatitis C-A quandary (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

Seeff LB

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

language of work or name

English

0 references

publication date

1 December 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

1710-1712

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Prognosis of chronic hepatitis C: results of a large, prospective cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

The natural history of chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Hepatitis C virus antibody, viral RNA and genotypes in leprous patients in Japan

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280636

7 January 2021

Identifiers

DOI

10.1002/HEP.510280636

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828240%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference